MedCity News

NOVEMBER 2, 2022

Alkermes says separating cancer from its portfolio and pipeline of neuroscience products could put the company on a path to profitability. Meanwhile, the new cancer company would be an independent and publicly traded entity with a lead immunotherapy in pivotal testing for two types of cancer.

Leads 118

Leads Biopharma Pharma 118

Fierce Pharma

JANUARY 10, 2024

Age 37 might be old for a “coming-out party,” but that’s the situation for Alkermes at this year’s J.P. Age 37 might be old for a “coming-out party,” but that’s the situation for Alkermes at this year’s J.P. Morgan Healthcare Conference, chief operating officer Blair Jackson said in an interview. |

Healthcare 228

Healthcare Healthcare 228

Fierce Pharma

JANUARY 4, 2024

Article by Richard Pops, CEO of Alkermes | Alkermes, a pioneer in neuroscience therapeutics, is building on its foundation as it emerges as a pure neuroscience company.

Leads 223

Leads Patients 223

Fierce Pharma

FEBRUARY 15, 2024

With the company revealing fourth-quarter sales of $56.2 million for Lybalvi, the olanzapine and samidorphan treatment is continuing its upward trajectory, helping trigger a 10% increase in the company's shares.

Sales 221

Sales 221

Fierce Pharma

JULY 26, 2023

Alkermes brought in $617 million during the second quarter, including $248 million of back royalties on Johnson & Johnson's Invega franchise. The company recently won an arbitration case against the pharma giant.

Sales 215

Sales Pharma 215

European Pharmaceutical Review

DECEMBER 15, 2023

Alkermes has agreed to sell its pharmaceutical development and manufacturing facility in Athlone, Ireland to Novo Nordisk for $92.5 The deal also includes around 400 staff employed by Alkermes in drug development and manufacturing. This is anticipated to be cost neutral to Alkermes over the subcontracting period.

Manufacturing 78

Manufacturing Engineering Pharmaceutical 78

PharmaVoice

FEBRUARY 6, 2024

With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.

69

69